Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (3)
Blood Cancer Journal (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Biotechnology
Cancer
Diseases
Immunology
Medical research
Microbiology
Neurology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–5 of 5 results

Advanced filters: Author: Deepu Madduri Clear advanced filters

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

This is a post hoc 18-month follow-up analysis of the CRB-401 trial, testing idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma, and reports sustained safety and clinical efficacy, which correlates with T cell phenotypes.

Yi Lin
Noopur S. Raje
James N. Kochenderfer
ResearchOpen Access17 Aug 2023
Nature Medicine

Volume: 29, P: 2286-2294
An inflammatory cytokine signature predicts COVID-19 severity and survival

Elevated levels of serum IL-6 and TNF-α at the time of hospitalization are independent and significant predictors of clinical outcome in two cohorts of patients with COVID-19.

Diane Marie Del Valle
Seunghee Kim-Schulze
Sacha Gnjatic
Research24 Aug 2020
Nature Medicine

Volume: 26, P: 1636-1643
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

A progressive movement disorder in a patient with multiple myeloma treated with anti-BCMA CAR-T cells that might have been related to on-target activity in the brain supports prospective neurologic monitoring after BCMA-targeting therapies.

Oliver Van Oekelen
Adolfo Aleman
Samir Parekh
Research10 Dec 2021
Nature Medicine

Volume: 27, P: 2099-2103
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen
Samir Parekh
Sundar Jagannath
ResearchOpen Access24 Feb 2022
Blood Cancer Journal

Volume: 12, P: 1-9
CAR-T cell therapy in Multiple Myeloma: current status and future challenges

Dawn Swan
Deepu Madduri
Jay Hocking
ReviewsOpen Access26 Nov 2024
Blood Cancer Journal

Volume: 14, P: 1-16